The excellent outcomes observed in patients with early-stage HER2-positive breast cancer treated with (neo)adjuvant HER2-directed therapy have led to successful optimization of regimens with fewer agents in patients with stage I HER2-positive breast cancer10,11. This evidence concerns the gene ERBB2 and breast carcinoma.